Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · IEX Real-Time Price · USD
5.89
-0.11 (-1.83%)
May 16, 2024, 4:00 PM EDT - Market closed
Editas Medicine Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Editas Medicine stock have an average target of 13.9, with a low estimate of 7.00 and a high estimate of 20. The average target predicts an increase of 135.99% from the current stock price of 5.89.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for EDIT stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 6 | 6 | 6 | 6 | 6 | 5 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $16 → $15 | Strong Buy | Maintains | $16 → $15 | +154.67% | May 9, 2024 |
| Morgan Stanley | Morgan Stanley | Sell → Hold Upgrades $7 | Sell → Hold | Upgrades | $7 | +18.85% | May 9, 2024 |
| Barclays | Barclays | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +52.80% | May 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $11 → $16 | Strong Buy | Maintains | $11 → $16 | +171.65% | Feb 29, 2024 |
| Barclays | Barclays | Hold Maintains $10 → $11 | Hold | Maintains | $10 → $11 | +86.76% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
37.10M
from 78.12M
Decreased by -52.51%
Revenue Next Year
29.58M
from 37.10M
Decreased by -20.27%
EPS This Year
-2.70
from -2.02
EPS Next Year
-2.73
from -2.70
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 82.6M | 70.1M | 254.1M | 693.1M | 881.9M |
| Avg | 37.1M | 29.6M | 77.4M | 188.8M | 313.8M |
| Low | n/a | n/a | 14.7M | 24.5M | 24.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 5.8% | 89.1% | 759.2% | 795.9% | 367.1% |
| Avg | -52.5% | -20.3% | 161.5% | 144.1% | 66.2% |
| Low | - | - | -50.3% | -68.3% | -87.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.93 | -1.80 | -1.49 | -0.99 | 1.29 |
| Avg | -2.70 | -2.73 | -2.87 | -2.16 | -1.01 |
| Low | -3.76 | -4.42 | -4.54 | -2.93 | -2.72 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.